Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...
Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema fell short of some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback